Ann Arbor Eye-Drug Developer ONL Therapeutics Raises 47-million Latest Venture Capital Round

This is an article about portfolio company, ONL Therapeutics Inc.

Ann Arbor-based pharmaceutical company ONL Therapeutics Inc. has closed on nearly $47 million in a Series B fundraising round that will further the company’s work on developing drugs to protect against several eye conditions that cause blindness. The investment was led by Fort Worth, Texas-based…

View source version on crainsdetroit.com: https://www.crainsdetroit.com/health-care/ann-arbor-eye-drug-developer-onl-therapeutics-raises-47-million-latest-venture-capital